PDCD1LG2 and neoplasm: Tumours carrying this mutation are characterised by the co-gain of PD-L1, PD-L2, and JAK2, and might benefit from immune checkpoint targeted therapies57,78,79 or adjuvant therapy with JAK2-specific inhibitors80,81.